Philip Morris International Inc.

What does Philip Morris International own?
PMI owns cigarette brands including Marlboro (international), Parliament, Chesterfield, L&M, and Bond Street, plus smoke-free brands IQOS, HEETS, TEREA, ZYN, and VEEV. It acquired nicotine pouch maker Swedish Match in 2022.

Is Philip Morris International publicly traded?
Yes. PMI trades on the New York Stock Exchange under ticker PM and is a component of the S&P 500. It spun off from Altria in 2008 and has no controlling shareholder.

Who founded Philip Morris?
The business traces to Philip Morris, who opened a London tobacco shop in 1847. Philip Morris International was incorporated in 1987 as the international arm and became independent in 2008.

Where is Philip Morris International headquartered?
PMI is headquartered in Stamford, Connecticut, USA, since 2022. Its primary operations center remains in Lausanne, Switzerland.

What is Philip Morris International's revenue?
PMI reported FY2025 net revenues of $40.6 billion, up 7.3% year over year. The smoke-free business contributed approximately 41.5% of total revenue, or close to $17 billion.

How many brands does Philip Morris International own?
PMI owns cigarette brands including Marlboro, Parliament, Chesterfield, L&M, and Bond Street, and smoke-free brands including IQOS, ZYN, and VEEV. Marlboro is the flagship, but smoke-free products now generate over 40% of revenue.

The business traces to 1847, when Philip Morris opened a tobacco shop on Bond Street in London. The company introduced Marlboro in 1924, initially targeted at women, before the brand's 1950s repositioning around the Marlboro Man cowboy made it the world's best-selling cigarette.

Philip Morris International was incorporated in 1987 as the international arm of Philip Morris Companies, the US conglomerate that also owned Kraft and Miller Brewing. The international operations were run from Switzerland, headquartered in Lausanne.

In March 2008, Altria Group, the renamed Philip Morris Companies, spun off Philip Morris International as a separate publicly traded company. The split separated the US cigarette business, subject to American litigation and FDA regulation, from the faster-growing international operations. Since the spin-off, PMI has operated independently and owns the Marlboro trademark everywhere outside the United States.

The defining strategic turn came in 2014, when PMI launched IQOS, a device that heats tobacco rather than burning it, in Nagoya, Japan and Milan, Italy. The company committed tens of billions of dollars to smoke-free product development and marketing, repositioning itself as a company that intends to phase out cigarette sales. In 2019 the FDA authorized IQOS for sale in the United States under a marketing order, though it is commercialized in the US through an arrangement with Altria.

In November 2022 PMI completed the approximately $16 billion acquisition of Swedish Match, the Stockholm-based oral nicotine company that makes ZYN pouches. The deal gave PMI the leading nicotine pouch brand in the US market, effectively re-entering American nicotine sales through the smoke-free category. In January 2025 the FDA authorized ZYN products for continued marketing after scientific review, a milestone for the brand.

PMI publishes an annual integrated report covering environmental, social, and governance topics, and has set science-based targets for emissions reductions across its supply chain, including tobacco agriculture. The company has achieved reductions in scope 1, 2, and 3 emissions and promotes sustainable tobacco farming standards through its Good Agricultural Practices program.

The central ethical question is product-related: PMI sells cigarettes while marketing its transition to smoke-free alternatives. Public health advocates argue that marketing heated tobacco and pouches, particularly flavored products appealing to younger demographics, creates new nicotine dependence rather than eliminating smoking harm. PMI maintains its products are intended for adult smokers as alternatives to cigarettes and points to regulatory authorizations, including FDA authorization of ZYN and IQOS marketing orders, as evidence of regulatory acceptance.

• Fortune 500: PMI ranks consistently on the Fortune 500 and Fortune Global 500 lists by revenue.
• Dow Jones Sustainability Indices: The company has been included in DJSI assessments, which evaluate corporate ESG performance.
• CDP ratings: PMI has received high CDP ratings for climate and water disclosure, including repeated A-list appearances.
• Employer certifications: The company holds Top Employer certification in numerous markets through the Top Employers Institute.

Ongoing tobacco litigation: PMI and predecessor entities have been subject to decades of tobacco litigation, including historical US cases resolved before the 2008 spin-off and ongoing international health-cost recovery and personal injury suits. The 1998 US Master Settlement Agreement applies to domestic manufacturers, not to PMI's international business.

FDA and regulatory scrutiny: PMI's smoke-free marketing claims, including "reduced risk" positioning for IQOS, have been closely examined by regulators. The FDA authorized IQOS for sale and later permitted modified exposure claims, while rejecting modified risk claims in 2020. ZYN received FDA marketing authorization in January 2025 after scrutiny of youth usage data.

Youth marketing concerns: Regulators and public health groups have raised concerns about flavored nicotine pouches and heated tobacco products appealing to adolescents. PMI states its marketing targets adult smokers only, but the debate continues as pouch use rises among younger demographics in several markets.

Plain packaging and taxation: Governments including Australia, France, the UK, and Canada have adopted plain packaging laws and steep excise regimes that constrain PMI's brand equity in cigarettes, though the company has mitigated the impact through pricing and premiumization.